2024
Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review
Turner N, Ko C, McNiff J, Galan A. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review. American Journal Of Dermatopathology 2024, 46: 21-30. PMID: 37982498, DOI: 10.1097/dad.0000000000002584.Peer-Reviewed Original ResearchConceptsConventional malignant melanomaMalignant melanomaPRAME immunohistochemistryBorderline lesionsNonmelanocytic lesionsDysplastic neviAmerican Joint CommitteePathological tumor stageMalignant melanocytic proliferationsBanal melanocytic nevusUlceration statusInstitution experienceBreslow depthMean ageTumor stageClinicopathologic correlationConsecutive casesMale genderAtypical fibroxanthomaSevere atypiaJoint CommitteeLarge seriesAmbiguous melanocytic lesionsMelanocytic proliferationMalignant counterparts
1999
Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma
Grossman D, McNiff J, Li F, Altieri D. Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma. Journal Of Investigative Dermatology 1999, 113: 1076-1081. PMID: 10594755, DOI: 10.1046/j.1523-1747.1999.00776.x.Peer-Reviewed Original ResearchConceptsInvasive malignant melanomaMalignant melanomaDominant negative mutantCultured normal human melanocytesCell cycle progressionApoptosis inhibitor Bcl-2G1 DNA contentNormal human melanocytesSurvivin expressionApoptosis inhibitor survivinApoptosis regulationEndogenous survivinNegative mutantTwo-color flow cytometryGenotoxic stimuliMalignant melanoma cell linesSurvivin dominant-negative mutantCycle progressionMetastatic malignant melanomaApoptosis inhibitorMelanoma cell linesHuman melanocytesMIB-1 stainingApoptosis inhibitionCases of nevus